197 related articles for article (PubMed ID: 20925442)
1. Pharmacokinetics of a new orodispersible tablet formulation of vardenafil: results of three clinical trials.
Heinig R; Weimann B; Dietrich H; Böttcher MF
Clin Drug Investig; 2011; 31(1):27-41. PubMed ID: 20925442
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials.
Sperling H; Gittelman M; Norenberg C; Ulbrich E; Ewald S
J Sex Med; 2011 Jan; 8(1):261-71. PubMed ID: 20807322
[TBL] [Abstract][Full Text] [Related]
3. Time to onset of action of vardenafil: a retrospective analysis of the pivotal trials for the orodispersible and film-coated tablet formulations.
Debruyne FM; Gittelman M; Sperling H; Börner M; Beneke M
J Sex Med; 2011 Oct; 8(10):2912-23. PubMed ID: 21883954
[TBL] [Abstract][Full Text] [Related]
4. Vardenafil orodispersible tablet.
Sanford M
Drugs; 2012 Jan; 72(1):87-98. PubMed ID: 22191797
[TBL] [Abstract][Full Text] [Related]
5. The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction.
Sperling H; Debruyne F; Boermans A; Beneke M; Ulbrich E; Ewald S
J Sex Med; 2010 Apr; 7(4 Pt 1):1497-507. PubMed ID: 20233275
[TBL] [Abstract][Full Text] [Related]
6. The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction.
Gittelman M; McMahon CG; Rodríguez-Rivera JA; Beneke M; Ulbrich E; Ewald S
Int J Clin Pract; 2010 Apr; 64(5):594-603. PubMed ID: 20456213
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects.
Damle B; Duczynski G; Jeffers BW; Crownover P; Coupe A; LaBadie RR
Clin Ther; 2014 Feb; 36(2):236-44. PubMed ID: 24447534
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of a new orally soluble film formulation of sildenafil administered without water.
Kim EY; Lee SY; Jeon JY; Im YJ; Kim Y; Kim HI; Shin KS; Park SJ; Seo YH; Lee JY; Park JK; Chae SW; Kim MG
Int J Clin Pharmacol Ther; 2014 Jun; 52(6):437-45. PubMed ID: 24786013
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: results of a randomized, placebo-controlled trial.
Schneider T; Gleissner J; Merfort F; Hermanns M; Beneke M; Ulbrich E
J Sex Med; 2011 Oct; 8(10):2904-11. PubMed ID: 21771281
[TBL] [Abstract][Full Text] [Related]
10. [Orally dissolving tablet levitra--a new step in the treatment of patients with erectile dysfunction].
Rasner PI; Pushkar' DIu
Urologiia; 2013; (4):93-6, 98. PubMed ID: 24159775
[No Abstract] [Full Text] [Related]
11. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic comparison of an orally disintegrating film formulation with a film-coated tablet formulation of sildenafil in healthy Korean subjects: a randomized, open-label, single-dose, 2-period crossover study.
Roh H; Son H; Lee D; Yeon KJ; Kim HS; Kim H; Park K
Clin Ther; 2013 Mar; 35(3):205-14. PubMed ID: 23497759
[TBL] [Abstract][Full Text] [Related]
13. Duration of erection: does it really matter? A randomized, double-blind clinical trial to assess the impact of vardenafil ODT on duration of erection and its correlation with patients' and partners' sexual quality of life and duration of intercourse: the VADEOPEN study.
Martin-Morales A; Gutiérrez-Hernández P; Romero-Otero J; Romero-Martín JA;
J Sex Med; 2014 Jun; 11(6):1527-38. PubMed ID: 24628736
[TBL] [Abstract][Full Text] [Related]
14. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study.
Rubio-Aurioles E; Porst H; Eardley I; Goldstein I
J Sex Med; 2006 Nov; 3(6):1037-1049. PubMed ID: 17100937
[TBL] [Abstract][Full Text] [Related]
15. High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension.
Sandqvist AM; Henrohn D; Schneede J; Hedeland M; Egeröd HC; Bondesson UG; Wikström BG
Eur J Clin Pharmacol; 2013 Feb; 69(2):197-207. PubMed ID: 22732766
[TBL] [Abstract][Full Text] [Related]
16. Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study.
Caglayan E; Axmann S; Hellmich M; Moinzadeh P; Rosenkranz S
Arch Intern Med; 2012 Aug; 172(15):1182-4. PubMed ID: 22710940
[No Abstract] [Full Text] [Related]
17. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction.
Rajagopalan P; Mazzu A; Xia C; Dawkins R; Sundaresan P
J Clin Pharmacol; 2003 Mar; 43(3):260-7. PubMed ID: 12638394
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and bioequivalence of sildenafil granules and sildenafil tablets in Korean healthy volunteers.
Zheng R; Kim BH
Int J Clin Pharmacol Ther; 2014 Jun; 52(6):530-6. PubMed ID: 24786017
[TBL] [Abstract][Full Text] [Related]
19. The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype.
Shon JH; Ku HY; Bae SY; Oh MK; Yeo CW; Bae SK; Shin JG
Pharmacogenet Genomics; 2011 Dec; 21(12):820-8. PubMed ID: 21934637
[TBL] [Abstract][Full Text] [Related]
20. [Effective and safe use of Levitra (Vardenafil) for treatment of erectile dysfunction].
Mazo EB; Gamidov SI; Ovchinnikov RI
Urologiia; 2004; (3):58-66. PubMed ID: 15199819
[No Abstract] [Full Text] [Related]
[Next] [New Search]
